Therefore, the results of the present study indicate that improved BP variability with dapagliflozin partially contributed to the amelioration of DN, and this is the first report to show that SGLT2 inhibitors can not only lower mean BP levels but also improve the quality of BP control. The gene discussed is SLC5A2; the disease is liver dysplastic nodule.